CY1109444T1 - Φαρμακευτικη συνθεση που περιεχει κυκλικα αναλογα σωματοστατινης - Google Patents

Φαρμακευτικη συνθεση που περιεχει κυκλικα αναλογα σωματοστατινης

Info

Publication number
CY1109444T1
CY1109444T1 CY20091101022T CY091101022T CY1109444T1 CY 1109444 T1 CY1109444 T1 CY 1109444T1 CY 20091101022 T CY20091101022 T CY 20091101022T CY 091101022 T CY091101022 T CY 091101022T CY 1109444 T1 CY1109444 T1 CY 1109444T1
Authority
CY
Cyprus
Prior art keywords
pharmaceutical composition
composition containing
somatostatin analogues
cyclical
containing cyclical
Prior art date
Application number
CY20091101022T
Other languages
English (en)
Inventor
Oliver Lambert
Katrin Moser
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33554159&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1109444(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0314695A external-priority patent/GB0314695D0/en
Priority claimed from GB0325388A external-priority patent/GB0325388D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY1109444T1 publication Critical patent/CY1109444T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C07K14/6555—Somatostatins at least 1 amino acid in D-form

Abstract

Η παρούσα εφεύρεση περιγράφει παρεντερικές φαρμακευτικές συνθέσεις που περιέχουν ανάλογο σωματοστατίνης και πρωτότυπα ανάλογα σωματοστατίνης.
CY20091101022T 2003-06-24 2009-09-30 Φαρμακευτικη συνθεση που περιεχει κυκλικα αναλογα σωματοστατινης CY1109444T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0314695A GB0314695D0 (en) 2003-06-24 2003-06-24 Organic compounds
GB0325388A GB0325388D0 (en) 2003-10-30 2003-10-30 Organic compounds
EP04740213A EP1648934B1 (en) 2003-06-24 2004-06-23 Pharmaceutical composition comprising cyclic somatostatin analogues

Publications (1)

Publication Number Publication Date
CY1109444T1 true CY1109444T1 (el) 2014-08-13

Family

ID=33554159

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091101022T CY1109444T1 (el) 2003-06-24 2009-09-30 Φαρμακευτικη συνθεση που περιεχει κυκλικα αναλογα σωματοστατινης

Country Status (32)

Country Link
US (3) US20070093412A1 (el)
EP (1) EP1648934B1 (el)
JP (1) JP4746541B2 (el)
KR (1) KR101124136B1 (el)
AR (1) AR044852A1 (el)
AT (1) ATE438659T1 (el)
AU (1) AU2004251866B2 (el)
BR (1) BRPI0411820B8 (el)
CA (1) CA2529449C (el)
CL (1) CL2004001579A1 (el)
CO (1) CO5650225A2 (el)
CY (1) CY1109444T1 (el)
DE (1) DE602004022420D1 (el)
DK (1) DK1648934T3 (el)
EC (1) ECSP056237A (el)
ES (1) ES2328144T3 (el)
HK (1) HK1089776A1 (el)
HR (1) HRP20090571T1 (el)
IL (1) IL172329A (el)
IS (1) IS2705B (el)
MA (1) MA27862A1 (el)
MX (1) MXPA05013821A (el)
MY (1) MY145375A (el)
NO (1) NO330706B1 (el)
NZ (1) NZ544157A (el)
PE (1) PE20050285A1 (el)
PL (1) PL1648934T3 (el)
PT (1) PT1648934E (el)
RU (1) RU2355418C2 (el)
SI (1) SI1648934T1 (el)
TW (1) TWI361194B (el)
WO (1) WO2005000893A2 (el)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2224947T3 (pl) 2007-11-28 2015-08-31 Novartis Ag Zastosowanie analogów somatostatyny w leczeniu oponiaka
WO2009071460A2 (en) * 2007-12-03 2009-06-11 Italfarmaco Spa New non-selective somatostatin analogues
FR2942227B1 (fr) * 2009-02-13 2011-04-15 Guerbet Sa Utilisation de tampons pour la complexation de radionucleides
TWI633887B (zh) 2012-05-31 2018-09-01 大塚製藥股份有限公司 用於預防及／或治療多囊性腎臟病之藥物
KR20160062023A (ko) * 2013-09-30 2016-06-01 오노 야꾸힝 고교 가부시키가이샤 소마토스타틴 수용체 작동 활성을 갖는 화합물 및 그 의약 용도
CN104447962B (zh) * 2014-12-29 2018-07-17 成都圣诺生物科技股份有限公司 一种合成帕瑞肽的方法
GB201816637D0 (en) 2018-10-12 2018-11-28 Heptares Therapeutics Ltd Selective somatostatin receptor agonists

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4328214A (en) * 1979-07-04 1982-05-04 Ciba-Geigy Corporation Cyclopeptides and pharmaceutical preparations thereof and also processes for their manufacture
DE3264693D1 (en) * 1981-12-24 1985-08-14 Ciba Geigy Ag Cyclic octapeptides and pharmaceutical compositions thereof, and processes for their production and use
US4612366A (en) * 1985-06-17 1986-09-16 Merck & Co., Inc. Cyclic hexapeptide somatostatin analogs
JPH02111A (ja) * 1987-08-03 1990-01-05 Toyo Jozo Co Ltd 経鼻投与用生理活性ペプチド製剤
US5059587A (en) * 1987-08-03 1991-10-22 Toyo Jozo Company, Ltd. Physiologically active peptide composition for nasal administration
JP2641755B2 (ja) 1988-01-29 1997-08-20 住友製薬株式会社 コントロールリリース製剤
HU221294B1 (en) * 1989-07-07 2002-09-28 Novartis Ag Process for producing retarde compositions containing the active ingredient in a polymeric carrier
PH30995A (en) * 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5716596A (en) 1992-06-23 1998-02-10 Diatide, Inc. Radioactively labeled somatostatin-derived peptides for imaging and therapeutic uses
ES2158897T3 (es) 1993-06-23 2001-09-16 Diatide Inc Peptidos radiomarcados derivados de somatostatina y utilizados en procedimientos de formacion de imagenes y terapeuticos.
US5453425A (en) 1994-07-11 1995-09-26 Janssen Pharmaceutica N.V. Risperidone oral formulation
MY147327A (en) * 1995-06-29 2012-11-30 Novartis Ag Somatostatin peptides
ES2167189B1 (es) 1999-12-17 2003-04-01 Lipotec Sa Formulacion farmaceutica estable para la administracion intravenosa o intramuscular, de principios activos peptidicos
GB0018891D0 (en) * 2000-08-01 2000-09-20 Novartis Ag Organic compounds
US7098305B2 (en) * 2001-09-06 2006-08-29 Ardana Bioscience Limited Sustained release of microcrystalline peptide suspensions
EP2310042B1 (en) * 2008-07-08 2012-12-05 Novartis AG Use of pasireotide for the treatment of endogenous hyperinsulinemic hypoglycemia

Also Published As

Publication number Publication date
TW200514789A (en) 2005-05-01
SI1648934T1 (sl) 2010-01-29
JP4746541B2 (ja) 2011-08-10
IS2705B (is) 2010-12-15
MY145375A (en) 2012-01-31
EP1648934B1 (en) 2009-08-05
US20090137462A1 (en) 2009-05-28
RU2355418C2 (ru) 2009-05-20
NZ544157A (en) 2008-07-31
NO20060375L (no) 2006-01-24
AU2004251866A1 (en) 2005-01-06
PL1648934T3 (pl) 2010-01-29
EP1648934A2 (en) 2006-04-26
BRPI0411820B8 (pt) 2021-05-25
WO2005000893A2 (en) 2005-01-06
BRPI0411820B1 (pt) 2019-06-25
US20130035286A1 (en) 2013-02-07
ECSP056237A (es) 2006-04-19
CL2004001579A1 (es) 2005-05-20
AU2004251866B2 (en) 2008-06-12
MXPA05013821A (es) 2006-02-28
CA2529449C (en) 2012-05-15
US20070093412A1 (en) 2007-04-26
ATE438659T1 (de) 2009-08-15
TWI361194B (en) 2012-04-01
ES2328144T3 (es) 2009-11-10
IL172329A (en) 2013-12-31
RU2006101720A (ru) 2007-08-10
AR044852A1 (es) 2005-10-05
CA2529449A1 (en) 2005-01-06
WO2005000893A3 (en) 2005-04-07
KR20060030052A (ko) 2006-04-07
DK1648934T3 (da) 2009-10-26
CO5650225A2 (es) 2006-06-30
IS8247A (is) 2006-01-20
US8299209B2 (en) 2012-10-30
KR101124136B1 (ko) 2012-03-21
IL172329A0 (en) 2009-02-11
JP2007536195A (ja) 2007-12-13
DE602004022420D1 (de) 2009-09-17
PE20050285A1 (es) 2005-06-09
MA27862A1 (fr) 2006-04-03
PT1648934E (pt) 2009-10-23
HK1089776A1 (en) 2006-12-08
NO330706B1 (no) 2011-06-20
BRPI0411820A (pt) 2006-08-08
HRP20090571T1 (en) 2009-11-30

Similar Documents

Publication Publication Date Title
CY1122370T1 (el) Συνθεσεις που περιεχουν φθοριο yποκατeστημενες ολεφινες
CY1109444T1 (el) Φαρμακευτικη συνθεση που περιεχει κυκλικα αναλογα σωματοστατινης
LTC1608344I2 (lt) Per burną vartojamos kladribino kompozicijos
HRP20080564T3 (en) Dihydrotetrabenazines and pharmaceutical compositions containing them
MY138074A (en) Somatostatin analogues
CY1109010T1 (el) γ-ΚΡΥΣΤΑΛΛΙΚΗ ΜΟΡΦΗ ΤΗΣ ΥΔΡΟΧΛΩΡΙΚΗΣ ΙΒΑΒΡΑΔΙΝΗΣ, ΜΕΘΟΔΟΣ ΠΑΡΑΣΚΕΥΗΣ ΤΗΣ ΚΑΙ ΦΑΡΜΑΚΕΥΤΙΚΕΣ ΣΥΝΘΕΣΕΙΣ ΠΟΥ ΤΗΝ ΠΕΡΙΕΧΟΥΝ
CY1112950T1 (el) Νηματωδοκτονες συνθεσεις
CY1108797T1 (el) Α-κρυσταλλικη μορφη του ρανελικου στροντιου, μεθοδος παρασκευης της και φαρμακευτικες συνθεσεις που την περιεχουν
NO20063393L (no) Farmasoytiske preparater
BRPI0408895A (pt) formulações de cladribina para administração oral e transmucosal aperfeiçoada
TNSN06012A1 (en) Emulsifying systems containing azetidine derivatives
CY1108226T1 (el) Αντικαρκινικες ενωσεις βασισμενες σε καχαλαλιδης f
NO20063293L (no) Farmasoytiske forbindelser
EA200600590A1 (ru) Фармацевтические композиции модафинила с модифицированным высвобождением
ITMI20022022A1 (it) Analoghi di nocicettina.
DE60300711D1 (de) Härtbare Zusammensetzungen
DE60331541D1 (de) Gaserzeugende Zusammensetzung
SI1729794T1 (sl) Farmacevtski pripravek, ki vsebuje sulfobetain, ki nima lastnosti detergenta
DK1919867T3 (da) Lisofyllinanaloger og farmaceutiske anvendelser heraf
TNSN05310A1 (en) Pharmaceutical composition comprising cyclic somatostatin analogues
DE60216332D1 (de) Antioxydationsmittel aus natürlicher quelle
HN2002000331A (es) Composiciones farmaceuticas de 5,7,14-triazatetra-ciclo (10.3.1.02,11.04,9)-hexadeca-2(11) 3,5,7,9-pentaeno